OM
TENX icon

Opaleye Management’s Tenax Therapeutics TENX Stock Holding History

Opaleye Management’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-12
Closed -$905K – 46
2016
Q3 		$905K Sell
12
-3
-20% -$237K 0.47% 39
2016
Q2 		$1.19M Sell
15
-1
-6% -$83.4K 0.79% 43
2016
Q1 		$1.02M Sell
16
-1
-6% -$77.7K 0.64% 42
2015
Q4 		$1.77M Sell
17
-3
-15% -$311K 0.74% 43
2015
Q3 		$1.91M Hold
20
– – 0.94% 38
2015
Q2 		$2.34M Buy
20
+1
+5% +$114K 0.93% 34
2015
Q1 		$1.98M Buy
19
+5
+36% +$525K 0.92% 30
2014
Q4 		$1.69M Buy
+14
New +$1.69M 0.85% 32

Other funds holding TENX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Opaleye Management's TENX Position: Q4 2016 in Review

Opaleye Management sold out of Tenax Therapeutics (TENX) in Q4 2016, closing a stake of 12 shares — an estimated $905K sold.

Opaleye Management first reported a position in TENX in Q4 2014 and held it in 8 quarters. The position peaked at $2.34M in Q2 2015. 19 funds tracked by Wall St. Rank hold TENX as of Q4 2016.

  • Opaleye Management reported no remaining Tenax Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Opaleye Management sold 12 Tenax Therapeutics shares in Q4 2016, an estimated $905K.
  • Opaleye Management first reported a position in Tenax Therapeutics in Q4 2014 and held it in 8 quarters.
  • Opaleye Management's Tenax Therapeutics position peaked at $2.34M in Q2 2015.
  • 19 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q4 2016.

Based on Opaleye Management's 13F filing for Q4 2016, filed 21 Feb 2017.